Establishing efficacy of a new experimental treatment in the 'gold standard' design

Area of Science:

• Clinical trial design
• Pharmacology
• Regulatory science

Background:

• Placebo-controlled trials are standard for demonstrating new drug efficacy.
• Statistical significance alone is insufficient; clinical relevance must also be proven.
• Defining clinical relevance a priori is a significant challenge.

Purpose of the Study:

• To address the challenge of defining clinically relevant differences in efficacy.
• To explore the utility of three-arm studies with active controls.
• To outline conditions for the gold standard design, focusing on assay sensitivity.

Main Methods:

• Conceptual analysis of clinical trial designs.
• Focus on a three-arm study including an active control group.
• Examination of assay sensitivity in the context of efficacy claims.

Main Results:

• A three-arm study design with an active control can resolve the issue of defining clinical relevance.
• Specific conditions within the gold standard design are necessary for robust efficacy claims.
• Assay sensitivity is a critical factor in establishing treatment efficacy.

Conclusions:

• Three-arm trials offer a solution for demonstrating both statistical and clinical significance.
• Careful design, including an active comparator, is crucial for regulatory acceptance.
• The proposed approach enhances the validity of new experimental treatment efficacy claims.